Target intelligence / Profile preview

Kallikrein-related peptidase 7 (KLK7) (KLK7)

Target
KLK7
Molecular classification
Enzyme, Serine protease, Peptidase
01

Overview

Kallikrein-related peptidase 7 (KLK7), also known as stratum corneum chymotryptic enzyme (SCCE), is a secreted serine protease predominantly expressed in the epidermis. It plays a crucial role in skin desquamation by catalyzing the degradation of intercellular cohesive structures, such as corneodesmosomes, in the stratum corneum. Under physiological conditions, this activity facilitates the continuous shedding of outer epidermal cells. However, pathological overexpression or dysregulation of KLK7 is a major driver of skin barrier disruption, chronic itch, and inflammation in diseases such as atopic dermatitis, Netherton syndrome, and psoriasis. Beyond dermatology, elevated KLK7 levels are associated with tumor progression, invasion, and metastasis in several malignancies, including ovarian, pancreatic, and breast cancers. Therapeutic strategies targeting KLK7 primarily focus on monoclonal and bispecific antibodies (such as TRIV-509 and TRIV-573) that inhibit its enzymatic activity, thereby restoring epidermal barrier integrity and alleviating inflammatory symptoms.

Other names
Kallikrein-7Stratum corneum chymotryptic enzymeSCCEhK7PRSS6Serine protease 6Kallikrein 7 (chymotryptic, stratum corneum)
02

Mechanism of action

Inhibition of Kallikrein-7 enzymatic activity (often dual inhibition with Kallikrein-5) to prevent degradation of corneodesmosomes, restore skin barrier integrity, and reduce inflammation and itch.

03

Biological functions

ProteolysisDesquamationEpidermal homeostasisImmune responseInflammationItch sensationCell migrationCell invasion
04

Disease associations

Atopic dermatitisNetherton syndromePsoriasisCancerOvarian cancerPancreatic cancerBreast cancerRosacea
05

Safety considerations

Impaired desquamation if over-inhibitedPotential off-target serine protease inhibitionSkin irritation or barrier disruption if homeostasis is perturbedImmunogenicity of therapeutic antibodies
06

Interacting drugs

2 more in the full profile.

07

Biomarkers

KLK7 expression levelKLK7 activityDesmoglein-1 (DSG1) degradationTh2 cytokines (e.g., TARC, pSTAT6)Transepidermal water loss (TEWL)

Beyond the preview

Go deeper on Kallikrein-related peptidase 7 (KLK7) (KLK7).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kallikrein-related peptidase 7 (KLK7) (KLK7).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call